AstraZeneca Productivity Savings Unlikely To Be Sustained Into 2006
This article was originally published in The Pink Sheet Daily
Executive Summary
High gross margin will be hard to maintain due to completion of one-time cost-reduction initiatives, increased marketing support and higher R&D spending.